10q10k10q10k.net
Axogen, Inc.

Axogen, Inc.AXGNEarnings & Financial Report

Nasdaq · biotechnology

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

NextMar 31, 2026

AXGN Q3 2025 Key Financial Metrics

Revenue

$60.1M

Gross Profit

$46.0M

Operating Profit

$1.9M

Net Profit

$708.0K

Gross Margin

76.6%

Operating Margin

3.2%

Net Margin

1.2%

YoY Growth

23.5%

EPS

$0.01

Financial Flow

Axogen, Inc. Q3 2025 Financial Summary

Axogen, Inc. reported revenue of $60.1M for Q3 2025, with a net profit of $708.0K (1.2% margin). Cost of goods sold was $14.1M, operating expenses totaled $44.1M.

Key Financial Metrics

Total Revenue$60.1M
Net Profit$708.0K
Gross Margin76.6%
Operating Margin3.2%
Report PeriodQ3 2025

Axogen, Inc. Annual Revenue by Year

Axogen, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $187.3M).

YearAnnual Revenue
2024$187.3M
2023$159.0M
2022$138.6M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$42.9M$41.4M$47.9M$48.6M$49.4M$48.6M$56.7M$60.1M
YoY Growth18.7%12.9%25.6%17.9%15.1%17.4%18.3%23.5%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$196.8M$186.5M$188.9M$192.0M$203.7M$196.2M$205.5M$216.4M
Liabilities$101.2M$93.4M$93.2M$92.6M$99.8M$90.8M$93.2M$95.6M
Equity$95.7M$93.2M$95.7M$99.4M$103.9M$105.4M$112.3M$120.8M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$-211000$-12.3M$4.2M$3.9M$8.7M$-13.2M$7.7M$3.2M